In the TTC trials, semaglutide group showed a marked reduction in infarct size and a considerable improvement in LVFS, LVEF, CO and SV, whereas the I/R group showed a marked increase in infarct size (Figures 2B, C)
Activation of these receptors might reduce de novo lipogenesis (the livers process of making new fat)
User should check the polarity of the battery cable and charger lead carefully before the connection to avoid any short circuit
Seek urgent medical advice if you experience very high readings, excessive thirst, frequent urination, dehydration, vomiting, abdominal pain, drowsiness, confusion, or rapid breathing, which could indicate serious hyperglycaemia or HHS requiring immediate attention
Keeping an eye on this trial, as we are hearing many positive anecdotes from POTS/assorted dysautonomia patients about symptom improvement and reduced inflammation on GLP-1 meds